Current Report Filing (8-k)
March 05 2021 - 04:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 5, 2021 (March 4, 2021)
Allena Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
DELAWARE |
|
001-38268 |
|
45-2729920 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
One Newton Executive Park, Suite 202
Newton, Massachusetts
|
|
02462 |
(Address of
principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code (617) 467-4577
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Securities registered or to be registered pursuant to
Section 12(b) of the Act.
|
|
|
|
|
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
per share |
|
ALNA |
|
The Nasdaq Global Select
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. ☒
Item 5.08 |
Shareholder Director Nominations
|
On March 4, 2021, the board of directors (the “Board”) of
Allena Pharmaceuticals, Inc. (the “Company”) established
June 3, 2021, as the date for the Company’s 2021 Annual
Meeting of Stockholders (the “Annual Meeting”) and set
April 5, 2021, as the record date for the Annual Meeting. Due
to the fact that the date of the Annual Meeting has been changed by
more than thirty (30) days from the anniversary date of the
2020 Annual Meeting of Stockholders, the Company is providing the
due date for submission of any qualified stockholder proposal or
qualified stockholder nominations.
In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and the Company’s
amended and restated bylaws (the “Bylaws”), the deadline for
receipt of stockholder proposals or nominations for inclusion in
the Company’s proxy statement for the Annual Meeting pursuant to
Rule 14a-8 will be no later
than 5:00 p.m., Eastern Time, March 15, 2021, or the tenth
(10th) day
following this public announcement of the meeting date. Stockholder
proposals must comply with all of the applicable requirements set
forth in the rules and regulations of the Securities and Exchange
Commission, including Rule 14a-8 under the Exchange Act and the
Bylaws. Stockholder proposals and director nominations should be
addressed to our Secretary, c/o Allena Pharmaceuticals, Inc., One
Newton Executive Park, Suite 202, Newton, MA 02462.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: March 5, 2021 |
|
Allena Pharmaceuticals,
Inc. |
|
|
|
|
|
By: |
|
/s/ Richard D. Katz
|
|
|
|
|
Richard D. Katz, MD |
|
|
|
|
Chief Financial Officer |